CERTIFICATE UNDER 37 CFR § 1.10 OF MAILING BY "EXPRESS MAIL" November 5, 2007 EV 758328329 US Date of Deposit USPS Express Mail Label Number I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Step Amendmen er for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. S Form PTO/SB/08: Substitute for form 1449A/PT9 Complete if Known 10/748,112 Application Number INFORMATION DISCLOSURE 5 2007 Piling Date December 29, 2003 Sanjay D. KHARE First Named Inventor 0 5 200STATEMENT BY APPLY 1644 Art Unit (Use as many sheets as necessary) Ilia I. OUSPENSKI Examiner Name Attorney Docket Number 06843.0052-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS							
miner Cite	Document Number	Issue or	Name of Patentee or	Pages, Columns, Lines, Where			
tials No.	Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			

	FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document Country Code Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation			

NONPATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		EMERY et al., "Improvement in health-related quality of life in patients with active rheumatoid arthritis: CTLA4lg combined with etanercept compared to etanercept plus placebo," <i>Arthritis Rheum.</i> , 46:S514, 1376, Abstract (2002).				
		BENDELE et al., "Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis," <i>Arthritis & Rheumatism</i> , 43:2648-2659 (2000).				
		FELDMANN et al., "Anti-TNFα therapy of rheumatoid arthritis: What have we learned?," Annu. Rev. Immunol., 19:163-196 (2001).				
		HARAOUI et al., "Biologic agents in the treatment of rheumatoid arthritis," Current Pharmaceutical Biotechnology, 1:217-233 (2000).				
		LORENZ et al., "Biologicl agents: a novel approach to the therapy of rheumatoid arthritis," Exp. Opin. Invest. Drugs, 9:1479-1490 (2000).				
		LU et al., "Effects of virus expressing CTLA4-IG and IL1-RA on islet Xenografts," <i>Transplantation Proceedings</i> , 33:713-714 (2001).				
		MORELAND et al., "Biological agents for treating rheumatoid arthritis," Arthritis & Rheumatism, 40:397-409 (1997).				
		TOTSUKA et al., "Therapeutic effect of anti-OX40L and anti-TNF-α MAbs in a murine model of chronic colitis," <i>Am.J.Physiol. Gastrointest.Liver Physiol.</i> , 284:G595-G603 (2003).				
		YOSHIOKA et al., "Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis," Eur. J. Immunol., 30:2815-2823 (2000).				
		WEINBERG et al., "Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease," <i>Molecular Medicine Today</i> , 4:76-83 (1998).				
		WEINBLATT et al., "A pilot, multi-center, randomized, double-blind, placebo controlled of a co-stimulation blocker CTLA4-lg (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis," Arthritis Rheum., 46:S204, 464, Abstract (2002).				
		WILLIAMS et al., "Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis," <i>Proc. Natl. Acad. Sci. USA</i> , 91:2762-2766 (1994).				
		Supplementary Partial European Search Report dated August 13, 2007, in European Patent Application No. 03800236.6 - 2406				
		Date				
Examiner Signature	1	Considered				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.